PharmacoEconomics

, Volume 24, Issue 8, pp 767–781

Pharmacoeconomic Analyses of Azathioprine, Methotrexate and Prospective Pharmacogenetic Testing for the Management of Inflammatory Bowel Disease

  • Virginia L. Priest
  • Evan J. Begg
  • Sharon J. Gardiner
  • Christopher M. A. Frampton
  • Richard B. Gearry
  • Murray L. Barclay
  • David W. J. Clark
  • Paul Hansen
Original Research Article

Abstract

Objectives: To compare the cost effectiveness of azathioprine (AZA), methotrexate (MTX) and no immunosuppression for maintaining remission of moderate to severe inflammatory bowel disease (IBD) in New Zealand Caucasians, and to determine whether prospective testing for poor metabolisers of AZA by genotype or phenotype is cost effective.

Methods: Pharmacoeconomic models were developed to compare treatment costs and effects (QALYs) in theoretical populations of 1000 IBD patients over a 1-year period. Efficacy and tolerability profiles for AZA and MTX were taken from the literature. The costs (year 2004 values) of the drugs and treatment of adverse effects were estimated from New Zealand drug and service costs. Representations of the patients’ health-related quality of life (HR-QOL) were obtained from clinicians via the EQ-5D health state classification system and valued using the New Zealand EQ-5D social tariff. The effects of genotyping or phenotyping a population for thiopurine methyltransferase (TPMT) status were compared using the prevalence of TPMT deficiency in Caucasians, the relative risks of neutropenia and the associated costs.

Results: Net cost savings (vs no immunosuppressant treatment) of approximately $NZ2.5 million and $NZ1 million were realised for AZA and MTX, respectively, for the theoretical 1000 patients, and AZA generated 877 QALYs compared with 633 for MTX. Phenotype and genotype testing generated net cost savings (vs no testing) of $NZ120 000 and $NZ11 000, respectively. Savings related to phenotype tests were greater because of the lower assay costs of phenotype testing and a greater likelihood of pre-empting neutropenia.

Conclusion: Our model suggests that both MTX and AZA may generate significant net cost savings and benefits for patients with IBD in New Zealand, with AZA likely to be more cost effective than MTX. Prospective testing for poor metabolisers of AZA may also be cost effective, with phenotype testing likely to be more cost effective than genotype testing.

References

  1. 1.
    Janowitz HD. Inflammatory bowel disease: a clinical approach. New York: Oxford University Press, 1994: 8–158Google Scholar
  2. 2.
    Knigge KL. Inflammatory bowel disease. Clin Cornerstone 2002; 4 (4): 49–60PubMedCrossRefGoogle Scholar
  3. 3.
    Rampton DS, Shanahan F. Inflammatory bowel disease. Oxford: Health Press, 2000Google Scholar
  4. 4.
    Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn’s Disease: Markov model analysis of a population-based cohort. Gastroenterology 1999; 117: 49–57PubMedCrossRefGoogle Scholar
  5. 5.
    Card T, Hubbard R, Logan RFA. Mortality in inflammatory bowel disease: a population based cohort study. Gastroenterology 2003; 125: 1583–90PubMedCrossRefGoogle Scholar
  6. 6.
    Arndt C, Balis F, McCully L. Bioavailability of low-dose verses lowdose 6-mercaptopurine. Clin Pharmacol Ther 1988; 45 (5): 588–91CrossRefGoogle Scholar
  7. 7.
    Van Os E, Zins BJ, Sandborn WJ, et al. Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration. Gut 1996; 39 (1): 63–8PubMedCrossRefGoogle Scholar
  8. 8.
    Feagan BG, Alfadhli A. Methotrexate in inflammatory bowel disease. Gastroenterol Clin North Am 2004; 33: 407–20PubMedCrossRefGoogle Scholar
  9. 9.
    Pearson DC, May GR, Fick G, et al. Azathioprine for maintenance of remission in Crohn’s disease. Available in The Cochrane Library [database on disk and CD-ROM]. Updated quaterly. The Cochrane Collaboration; issue 2. Oxford: Update Software, 2004Google Scholar
  10. 10.
    Markowitz JF. Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn’s Disease. Rev Gastroenterol Disord 2003; 3 Suppl. 1: S23–9PubMedGoogle Scholar
  11. 11.
    Gearry RB, Barclay M, Burt MJ, et al. Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease. Pharmacoepidemiol Drug Saf 2004; 13: 563–7PubMedCrossRefGoogle Scholar
  12. 12.
    Fraser AG, Morton D, McGovern D, et al. The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Phannacol Ther 2002; 16: 693–7CrossRefGoogle Scholar
  13. 13.
    Umann M, Chamoit-Prieur C, Mesnard B. Methotrexate for the treatment of refractory Crohn’s disease. Aliment Pharmacol Ther 1996; 10: 309–14CrossRefGoogle Scholar
  14. 14.
    Lemann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn’s disease: long-term efficacy and toxicity. Am J Gastroenterol 2000; 95 (7): 1730–4PubMedGoogle Scholar
  15. 15.
    Schnabel A, Gross WL. Low dose methotrexate in rheumatic diseases: efficacy, side effects, and risk factors for side effects. Semin Arthritis Rheum 1994; 23: 310–27PubMedCrossRefGoogle Scholar
  16. 16.
    Dubinsky M, Reyeas E, Of man J, et al. A cost-effectiveness analysis of alternative disease management strategies in patients treated with azathioprine or 6-mercaptopurine. Am J Gastroenterol 2005; 100: 2239–47PubMedCrossRefGoogle Scholar
  17. 17.
    Gardiner SJ, Begg EJ, Barclay ML, et al. Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine. Adverse Drug React Toxicol Rev 2000; 19 (4): 293–312PubMedGoogle Scholar
  18. 18.
    Schaeffeler E, Fischer C, Brockmeier D, et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a larger population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics 2004; 14 (7): 407–17PubMedCrossRefGoogle Scholar
  19. 19.
    Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics 2005; 15: 365–9PubMedCrossRefGoogle Scholar
  20. 20.
    Sies C, Florkowski C, George P, et al. Measurement of thiopurine methyl-transferase activity guides dose initiation and prevents toxicity from azathioprine. N Z Med J 2005; 118 (1210), 1–7Google Scholar
  21. 21.
    Weinshilboum RM. Human pharmacogenetics of methyl conjugation. Fed Proc 1984; 43 (8): 2303–7PubMedGoogle Scholar
  22. 22.
    Gardiner SJ, Gearry RB, Barclay ML, et al. Two cases of thiopurine methyltransferase (TPMT) deficiency: a lucky save and a near miss with azathioprine. Br J Clin Pharmacol. Epub 2005 Aug 1Google Scholar
  23. 23.
    Winter J, Walker A, Shapiro D, et al. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20: 593–9PubMedCrossRefGoogle Scholar
  24. 24.
    Bouhnik Y, Lemann M, Mary J-Y, et al. Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347: 215–9PubMedCrossRefGoogle Scholar
  25. 25.
    Chong RY, Hanauer SB, Cohen RD. Efficacy of paraenteral methotrexate in refractory Crohn’s disease. Aliment Pharmacol Ther 2001; 15: 35–44PubMedCrossRefGoogle Scholar
  26. 26.
    Feagan BG, Fedorak RN, Irvine J, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s Disease. N Engl J Med 2000; 342: 1627–32PubMedCrossRefGoogle Scholar
  27. 27.
    Friedman S. General principles of medical therapy of Inflammatory Bowel Disease. Gastroenterol Clin North Am 2004; 33: 191–208PubMedCrossRefGoogle Scholar
  28. 28.
    Pearson DC, May GR, Fick G, et al. Azathioprine and 6-mercaptopurine in Crohn’s Disease: a meta analysis. Ann Intern Med 1995; 123 (2): 132–42PubMedGoogle Scholar
  29. 29.
    Chong RY, Hanauer SB, Cohen RD. Methotrexate in Crohn’s disease: how’s it doing? [abstract]. Gastroenterology 1998; 114: A951CrossRefGoogle Scholar
  30. 30.
    Bloomfield RS, Onken JE. Mercaptopurine metabolite results in clinical gastroenterology practice. Aliment Pharmacol Ther 2003; 17: 69–73CrossRefGoogle Scholar
  31. 31.
    Cunliffe RN, Scott BB. Monitoring for drug side effects in inflammatory bowel disease. Aliment Pharmacol Ther 2002; 16: 647–62PubMedCrossRefGoogle Scholar
  32. 32.
    Schroder O, Stein J. Low dose methotrexate in Inflammatory Bowel Disease: current status and future directions. Am J Gastroenterol 2003; 98 (3): 530–7PubMedCrossRefGoogle Scholar
  33. 33.
    Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for the maintenance of remission of Crohn’s Disease. Gastroenterology 2000; 118: 1018–24PubMedCrossRefGoogle Scholar
  34. 34.
    Kanik KS, Cash JM. Does methotrexate increase the risk of infection or malignancy? Rheum Dis Clin North Am 1997; 23: 955–67PubMedCrossRefGoogle Scholar
  35. 35.
    Present DH, Meltzer SJ, Krumholz MP, et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short and long-term toxicity. Ann Intern Med 1989; 111 (8): 641–9PubMedGoogle Scholar
  36. 36.
    Egan LJ, Sandborn WJ. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc 1996; 71: 69–80PubMedCrossRefGoogle Scholar
  37. 37.
    Weinshilboum RM, Sladek SL. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 1980; 32: 651–2PubMedGoogle Scholar
  38. 38.
    Pharmaceutical Management Agency. Pharmaceutical Schedule [online]. Available from: http://www.pharmac.govt.nz [Accessed 2004 Jul]Google Scholar
  39. 39.
    Canterbury Health Laboratories. Canterbury District Health Board. [online]. Available from: http://www.cdhb.govt.nz [Accessed 2004 Jul]Google Scholar
  40. 40.
    Roberts RL, Barclay ML, Gearry RB, et al. A multiplexed allele-specific polymerase chain reaction assay for the detection of common thiopurine S-methyltransferase (TPMT) mutations. Clin Chim Acta 2004; 341: 49–53PubMedCrossRefGoogle Scholar
  41. 41.
    Walmsley TA, Florkowski CM, George PM, et al. Thiopurine methyltransferase: radiochemical microassay and biochemical properties. N Z Med J 2002; 115: 302PubMedGoogle Scholar
  42. 42.
    Weinshilboum RM, Raymond FA, Pazmino PA. Human erythrocyte thiopurine methyl transferase: radiochemical microassay and biochemical properties. Clin Chim Acta 1978; 85: 323–33PubMedCrossRefGoogle Scholar
  43. 43.
    Devlin NJ, Hansen P, Kind P, et al. The health state preferences and local inconsistencies of New Zealanders: a tale of two tariffs. The University of York, Centre for Health Economics. University of Otago. 2000, Discussion Paper 180Google Scholar
  44. 44.
    Weinstein MC, Siegel JE, Gold MR, et al. Recommendation of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253–8PubMedCrossRefGoogle Scholar
  45. 45.
    Devlin NJ, Hansen P, Kind P, et al. Logical inconsistencies in survey respondents’ health state valuations: a methodological challenge for estimating social tariffs. Health Econ 2003; 12 (7) 529–44PubMedCrossRefGoogle Scholar
  46. 46.
    EQ-5D [online]. Available from URL: http://www.euroqol.org [Accessed 2006 Jun 22]Google Scholar
  47. 47.
    Jowett SL, Seal CJ, Barton JR, et al. The short Inflammatory Bowel Disease questionnaire is reliable and responsive to clinically important change in ulcerative colitis. Am J Gastroenterol 2001; 96: 2921–8PubMedCrossRefGoogle Scholar
  48. 48.
    Oh K-T, Anis AH, Bae S-C. Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea. Rheumatology 2004; 43: 156–63PubMedCrossRefGoogle Scholar
  49. 49.
    Marra CA, Esdaile JM, Anis AH. Practical pharmacogenetics: the cost-effectiveness of screening for thiopurine S-methyltransferase polymorphisms in patients with rheumatological conditions treated with azathioprine. J Rheumatol 2002; 29: 2507–12PubMedGoogle Scholar
  50. 50.
    Suarez-Alamazor ME, Spooner C, Belseck E. Azathioprine for treating rheumatoid arthritis. Available in The Cochrane Library [database on disk and CD-ROM]. Updated quaterly. The Cochrane Collaboration; issue 4. Oxford: Update Software, 2004Google Scholar
  51. 51.
    Krynetski EY, Evans WE. Genetic polymorphism of thiopurine S-methyltransferase: molecular rnxhanisms and clinical importance. Pharmacology 2000; 61: 136–46PubMedCrossRefGoogle Scholar
  52. 52.
    Cheung ST, Allan RN. Mistaken identity: misclassification of TPMT phenotype following blood transfusion. Eur J Gastroenterol Hepatol 2003; 15 (11): 1245–7PubMedCrossRefGoogle Scholar
  53. 53.
    Schwab M, Schaeffeler E, Marx C, et al. Shortcoming in the diagnosis of TPMT deficiency in a patient with Crohn’s Disease using phenotyping only. Gastroenterology 2001; 121: 500–1CrossRefGoogle Scholar
  54. 54.
    Pazmino PA, Sladek SL, Weinshilboum RM. Thiol S-methylation in uremia: erythrocyte enzyme activities and plasma inhibitors. Clin Pharmacol Ther 1980; 28: 356–67PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Virginia L. Priest
    • 1
    • 2
  • Evan J. Begg
    • 1
    • 3
  • Sharon J. Gardiner
    • 1
    • 3
  • Christopher M. A. Frampton
    • 3
  • Richard B. Gearry
    • 3
    • 4
  • Murray L. Barclay
    • 1
    • 4
  • David W. J. Clark
    • 2
    • 5
  • Paul Hansen
    • 6
  1. 1.Department of Clinical PharmacologyChristchurch HospitalChristchurchNew Zealand
  2. 2.Department of Pharmacology & ToxicologyUniversity of OtagoDunedinNew Zealand
  3. 3.Department of MedicineChristchurch School of MedicineChristchurchNew Zealand
  4. 4.Department of GastroenterologyChristchurch HospitalChristchurchNew Zealand
  5. 5.Intensive Medicines Monitoring Programme, Pharmacovigilance Centre, Department of Preventive & Social MedicineUniversity of OtagoDunedinNew Zealand
  6. 6.Department of EconomicsUniversity of OtagoDunedinNew Zealand

Personalised recommendations